Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Cohn, Jeffrey S.; Patterson, Bruce W.; Uffelman, Kris D.; Davignon, Jean; Steiner, George

doi:10.1210/jc.2003-032056

Cited by 170Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Cohn, Jeffrey S., Patterson, Bruce W., Uffelman, Kris D., Davignon, Jean, Steiner, George·2004·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2003-032056

Open this paper in CoChat — free account

Abstract

Overweight individuals with reduced insulin sensitivity often have mild to moderate hypertriglyceridemia. To investigate the role of apolipoprotein (apo)C-III metabolism in the etiology of hypertriglyceridemia in these individuals, we investigated 10 male subjects with different body weights (body mass index, 24-34 kg/m(2)) and insulin sensitivity (homeostasis model assessment, 4.7-35.0). Total plasma and very-low-density lipoprotein (VLDL) apoC-III kinetics, as well as VLDL triglyceride (TG) and VLDL apoB kinetics, were measured with iv injected stable isotopes. The apoC-III, TG, and apoB levels in VLDL ranged from 2.9-18.2 mg/dl, 0.49-2.89 mmol/liter, and 6.7-29.3 mg/dl, respectively. Mean production rates (PRs) were: VLDL apoC-III, 20.2 +/- 4.1 micromol/d (range, 8.0-44.8); VLDL TG, 26.9 +/- 4.6 mmol/d (range, 10.2-51.1); and VLDL apoB, 4.4 +/- 0.8 micromol/d (range, 1.5-9.1). VLDL apoC-III PRs were significantly correlated with body mass index, homeostasis model assessment, and plasma TG (r = 0.66, P < 0.05; r = 0.80, P < 0.01; r = 0.95, P < 0.001, respectively). Similar correlations were found for plasma apoC-III PRs (r = 0.70, P < 0.05; r = 0.67, P < 0.05; r = 0.80, P < 0.01, respectively). Fractional catabolic rates (FCRs) were not significantly related to metabolic variables. VLDL TG levels were strongly related to VLDL apoC-III levels (r = 0.99, P < 0.001) and VLDL apoC-III PRs (r = 0.94, P < 0.001). VLDL apoC-III levels were more strongly correlated with VLDL TG PRs (r = 0.81, P < 0.01) than with VLDL TG FCRs or VLDL apoB FCRs (r = -0.53, P = 0.12; r = -0.37, P = 0.29). These results suggest that increased hepatic production of VLDL apoC-III is characteristic of subjects with higher body weights and lower levels of insulin sensitivity and is strongly related to the plasma concentration and level of production of VLDL TG.

Integrity signals

Registry

Crossref · 10.1210/jc.2003-032056

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The increase in triglyceride production may be due to excess free fatty acids returning to the liver, particularly in visceral obesity and insulin resistance, and increased de novo triglyceride production due to hyperinsulinemia.
“The increase in triglyceride production may be due to excess free fatty acids returning to the liver, particularly in the setting of visceral obesity and insulin resistance, and increased de novo triglyceride production due to hyperinsulinemia (24,62,63).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [63]
Defective clearance of triglyceride-rich VLDL by LpL can contribute to moderate hypertriglyceridemia, and many patients have overproduction of VLDL triglyceride in the liver with increased secretion.
“Defective clearance of triglyceride-rich VLDL by LpL can contribute to this condition, and many patients have overproduction of VLDL triglyceride in the liver with an increased secretion (24,62,63).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [63]

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358 · see citing works
Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
Lewis, G. F., Carpentier, A. C., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,328 · see citing works
Hypertriglyceridemia as a Result of Human apo <i>CII</i> Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539 · see citing works
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539 · see citing works
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Brown, W. V., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 493 · see citing works
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto‐Setälä, K., Fisher, E. A. A., Chen, X., Chajek‐Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450 · see citing works
Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources
Havel, R. J., Fielding, C. J., Olivecrona, T., Shore, V. G., Fielding, P. E., & Egelrud, T. (1973) · Biochemistry · doi:10.1021/bi00733a026 · Cited by 332 · see citing works
Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals
Lewis, G. F., Uffelman, K. D., Szeto, L., & Steiner, G. A. (1993) · Diabetes · doi:10.2337/diab.42.6.833 · Cited by 323 · see citing works
Self-citation
Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver.
Windler, E. E. T., & Havel, R. J. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34342-x · Cited by 314 · see citing works
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.
Maeda, N., Li, H., Lee, D., Oliver, P. M., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313 · see citing works
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288 · see citing works
Transport of Very Low Density Lipoprotein Triglycerides in Varying Degrees of Obesity and Hypertriglyceridemia
Grundy, S. M., Mok, H. Y. I., Zech, L. A., Steinberg, D. H., & Berman, M. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109422 · Cited by 283 · see citing works
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278 · see citing works
An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms.
Dammerman, M., Sandkuijl, L. A., Halaas, J. L., Chung, W. K., & Breslow, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4562 · Cited by 227 · see citing works
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E.
de Silva, H. V., Lauer, S. J., Wang, J., Simonet, W. S., Weisgraber, K. H., Mahley, R. W., & Taylor, J. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42171-5 · Cited by 209 · see citing works
Prevention Conference VI: Diabetes and Cardiovascular Disease
Eckel, R. H., Wassef, M. K., Chait, A., Sobel, B. E., Barrett, E. J., King, G. L., Lopes-Virella, M. F., Reusch, J. E. B., Ruderman, N. B., Steiner, G. A., et al. (2002) · Circulation · doi:10.1161/01.cir.0000013954.65303.c5 · Cited by 199 · see citing works
Self-citation
Mechanisms of Hepatic Very Low-Density Lipoprotein Overproduction in Insulin Resistance
Adeli, K., Taghibiglou, C., Van Iderstine, S. C., & Lewis, G. F. (2001) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00084-6 · Cited by 194 · see citing works
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
Ebara, T., Ramakrishnan, R., Steiner, G. A., & Shachter, N. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119456 · Cited by 191 · see citing works
Self-citation
Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.
Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 184 · see citing works
Modulation of Lipoprotein B Binding to the LDL Receptor by Exogenous Lipids and Apolipoproteins CI, CII, CIII, and E
Barthelemy-Clavey, V., Lestavel-Delattre, S., Copin, C., Bard, J., & Fruchart, J. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.7.963 · Cited by 178 · see citing works
Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism
Cobelli, C., TOFFOLO, G. M., & Foster, D. M. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.262.6.e968 · Cited by 177 · see citing works
Apolipoprotein C-II and C-III levels in hyperlipoproteinemia
Schonfeld, G., George, P. K., Miller, J. P., Reilly, P., & Witztum, J. L. (1979) · Metabolism · doi:10.1016/0026-0495(79)90004-0 · Cited by 176 · see citing works
Influence of obesity on the metabolism of apolipoprotein B in humans.
Egusa, G., Beltz, W. F., Grundy, S. M., & Howard, B. V. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112011 · Cited by 167 · see citing works
Quantitative determination of human apolipoprotein Cc-III by electroimmunoassay
Curry, M. D., McConathy, W. J., Fesmire, J. D., & Alaupovic, P. (1980) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(80)90016-8 · Cited by 140 · see citing works
Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease.
Kesäniemi, Y. A., Beltz, W. F., & Grundy, S. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112010 · Cited by 140 · see citing works
Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration
Chan, D. C., Watts, G. F., Redgrave, T. G., Mori, T. A., & Barrett, P. H. R. (2002) · Metabolism · doi:10.1053/meta.2002.33339 · Cited by 133 · see citing works
Effect of sex and obesity on basal VLDL-triacylglycerol kinetics
Mittendorfer, B., Patterson, B. W., & Klein, S. (2003) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.3.573 · Cited by 132 · see citing works
Self-citation
Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity
Riches, F. M., Watts, G. F., Naoumova, R. P., Kelly, J., Croft, K. D., & Thompson, G. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800602 · Cited by 126 · see citing works
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Haubenwallner, S., Essenburg, A. D., Barnett, B. C., Pape, M. E., Demattos, R. B., Krause, B. R., Minton, L. L., Auerbach, B. J., Newton, R. S., & Leff, T. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41090-9 · Cited by 119 · see citing works
Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto‐Setälä, K., Weinstock, P. H., Bisgaier, C. L., Wu, L., Smith, J. D., & Breslow, J. L. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39123-9 · Cited by 114 · see citing works
Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions
Fredenrich, A., Giroux, L.-M., Tremblay, M., Krimbou, L., Davignon, J., & Cohn, J. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37424-1 · Cited by 114 · see citing works
Self-citation
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113 · see citing works
Self-citation
Polymorphic Markers in Apolipoprotein C-III Gene Flanking Regions and Hypertriglyceridemia
Surguchov, A. P., Page, G. P., Smith, L. C., Patsch, W., & Boerwinkle, E. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.8.941 · Cited by 108 · see citing works
Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM
Taskinen, M., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diab.39.9.1017 · Cited by 103 · see citing works
Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration
Malmendier, C. L., Lontie, J., Delcroix, C., Dubois, D. Y., Magot, T., & Roy, L. D. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90075-0 · Cited by 94 · see citing works
ApoCIII Gene Variants Modulate Postprandial Response to Both Glucose and Fat Tolerance Tests
Waterworth, D. M., Ribalta, J., Nicaud, V., Dallongeville, J., Humphries, S. E., & Talmud, P. J. (1999) · Circulation · doi:10.1161/01.cir.99.14.1872 · Cited by 85 · see citing works
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
von Eckardstein, A., Holz, H., Sandkamp, M., Weng, W., Funke, H., & Assmann, G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115190 · Cited by 81 · see citing works
Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor
Mann, C. J., Troussard, A. A., Yen, F. T., Hannouche, N., Najïb, J., Fruchart, J., Lotteau, V., André, P., & Bihain, B. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31348 · Cited by 77 · see citing works
ApoC-III gene polymorphisms and risk of coronary artery disease
Olivieri, O., Stranieri, C., Bassi, A., Zaia, B., Girelli, D., Pizzolo, F., Trabetti, E., Cheng, S., Grow, M. A., Pignatti, P. F., et al. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200145-jlr200 · Cited by 70 · see citing works
Early Kinetic Abnormalities of ApoB-Containing Lipoproteins in Insulin-Resistant Women With Abdominal Obesity
Pont, F., Duvillard, L., Florentin, E., Gambert, P., & Vergès, B. L. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000032134.92180.41 · Cited by 63 · see citing works
Familial HDL Deficiency Characterized by Hypercatabolism of Mature ApoA-I but Not ProApoA-I
Batal, R., Tremblay, M., Krimbou, L., Mamer, O., Davignon, J., Genest, J. J., & Cohn, J. S. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.4.655 · Cited by 61 · see citing works
Self-citation
Improved method for quantitation of B apoprotein in plasma lipoproteins by electroimmunoassay.
Reardon, M., Poapst, M. E., Uffelman, K. D., & Steiner, G. A. (1981) · Clinical Chemistry · doi:10.1093/clinchem/27.6.892 · Cited by 58 · see citing works
Self-citation
Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis.
Forte, T. M., Nichols, A. V., Krauss, R. M., & Norum, R. A. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111576 · Cited by 57 · see citing works
Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease.
Lee, S.-J., Moye, L. A., Campos, H., Williams, G. H., & Sacks, F. M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00007-8 · Cited by 50 · see citing works
Modulation of lipoprotein production in hep G2 cells by fenofibrate and clofibrate
Hahn, S. E., & Goldberg, D. M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90586-8 · Cited by 49 · see citing works
Effect of obesity on the relationship between very low density lipoprotein production rate and plasma triglyceride concentration in normal and hypertriglyceridemic subjects
Reaven, G. M., & Bernstein, R. M. (1978) · Metabolism · doi:10.1016/0026-0495(78)90150-6 · Cited by 49 · see citing works
A stable isotope method using a [2H5]glycerol bolus to measure very low density lipoprotein triglyceride kinetics in humans
Lemieux, S., Patterson, B. W., Carpentier, A. C., Lewis, G. F., & Steiner, G. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32434-2 · Cited by 45 · see citing works
Self-citation
Very low density lipoprotein metabolism in diabetes mellitus
Ginsberg, H. N. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030209 · Cited by 43 · see citing works
Sensitivity to Acute Insulin-Mediated Suppression of Plasma Free Fatty Acids Is Not a Determinant of Fasting VLDL Triglyceride Secretion in Healthy Humans
Carpentier, A. C., Patterson, B. W., Leung, N. M., & Lewis, G. F. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1867 · Cited by 41 · see citing works
Self-citation
A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia
Ribalta, J., Ville, A. E. L., Vallvé, J.-C., Humphries, S. E., Turner, P. R., & Masana, L. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37189-3 · Cited by 41 · see citing works
Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C
van Barlingen, H. H. J. J., de Jong, H., Erkelens, D. W., & de Bruin, T. W. A. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37573-8 · Cited by 39 · see citing works
Interactions Between Glucose and FFA Metabolism in Man
Saloranta, C., & Groop, L. (1996) · Diabetes/Metabolism Reviews · doi:10.1002/(sici)1099-0895(199603)12:1 · Cited by 37 · see citing works
Self-citation
Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men
Waterworth, D. M., Talmud, P. J., Luan, J., Flavell, D. M., Byrne, C. D., Humphries, S. E., & Wareham, N. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(03)00021-8 · Cited by 37 · see citing works
[5] Apolipoprotein B-48
Karpe, F., Hamsten, A., Uffelman, K. D., & Steiner, G. A. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)63007-9 · Cited by 35 · see citing works
Self-citation
Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase
Landis, B. A., Rotolo, F. S., Meyers, W. C., Clark, A. B., & Quarfordt, S. H. (1987) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1987.252.6.g805 · Cited by 32 · see citing works
Hyperinsulinemia and VLDL Kinetics
Steiner, G. A. (1993) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2910-1_22 · Cited by 4 · see citing works
Self-citation
Level of apoC-III mRNA correlates positively to the secretion of triglyceride-rich VLDL from transfected McA-RH7777 cells
Rahimkhani, S., Tran, K. T., Wang, Y., & Yao, Z. (2000) · Cited by 3 · see citing works

Flagged first, then by citations

Sorted by citations

Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works
“The increase in triglyceride production may be due to excess free fatty acids returning to the liver, particularly in the setting of visceral obesity and insulin resistance, and increased de novo triglyceride production due to hyperinsulinemia (24, 62, 63).”
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531 · see citing works
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463 · see citing works
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418 · see citing works
Fat Depots, Free Fatty Acids, and Dyslipidemia
Ebbert, J. O., & Jensen, M. D. (2013) · Nutrients · doi:10.3390/nu5020498 · Cited by 351 · see citing works
Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein–Proteome Remodeling
Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.108753 · Cited by 337 · see citing works
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · see citing works
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260 · see citing works
Causes and consequences of hypertriglyceridemia
Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239 · see citing works
Diabetic Dyslipidemia
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233 · see citing works
Genetically engineered pigs as models for human disease
Perleberg, C., Kind, A., & Schnieke, A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.030783 · Cited by 222 · see citing works
Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia
Sparks, J. D., Sparks, C. E., & Adeli, K. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241463 · Cited by 237 · see citing works
Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223 · see citing works
Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells
Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206 · see citing works
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0159-y · Cited by 188 · see citing works
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182 · see citing works
Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
Fisher, E. A. A., & Cohen, D. E. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358519 · Cited by 179 · see citing works
Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia
Deeg, M. A., Buse, J. B., Goldberg, R. B., Kendall, D. M., Zagar, A. J., Jacober, S. J., Khan, M. A., Perez, A. T., Tan, M. H., & on behalf of the GLAI Study Investigators (2007) · Diabetes Care · doi:10.2337/dc06-1903 · Cited by 179 · see citing works
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
Sundaram, M., Zhong, S., Khalil, M. B., Links, P. H., Zhao, Y., Iqbal, J., Hussain, M. M., Parks, R. J., Wang, Y., & Yao, Z. (2009) · Journal of Lipid Research · doi:10.1194/m900346-jlr200 · Cited by 170 · see citing works
The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia
Sacks, F. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000146 · Cited by 168 · see citing works
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201 · see citing works
Self-citation
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia
Caron, S., Verrijken, A., Mertens, I. L., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.220723 · Cited by 162 · see citing works
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects
Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224808 · Cited by 153 · see citing works
Hypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152 · see citing works
Role of triglyceride-rich lipoproteins in diabetic nephropathy
Rutledge, J. C., Ng, K. F., Aung, H. H., & Wilson, D. W. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.59 · Cited by 152 · see citing works
ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan
Hiukka, A., Ståhlman, M., Pettersson, C., Levin, M. C., Adiels, M., Teneberg, S., Leinonen, E. S., Hultén, L. M., Wiklund, O., Orešič, M., et al. (2009) · Diabetes · doi:10.2337/db09-0206 · Cited by 141 · see citing works
The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis
Wyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134 · see citing works
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance
Lee, H., Birkenfeld, A. L., Jornayvaz, F. R., Jurczak, M. J., Kanda, S., Popov, V., Frederick, D. W., Zhang, D., Guigni, B. A., Bharadwaj, K. G., et al. (2011) · Hepatology · doi:10.1002/hep.24571 · Cited by 134 · see citing works
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 126 · see citing works
Lipotoxicity as a trigger factor of renal disease
Izquierdo-Lahuerta, A., Martínez-García, C., & Medina-Gómez, G. (2016) · JN. Journal of Nephrology (Milano. 1992) · doi:10.1007/s40620-016-0278-5 · Cited by 110 · see citing works
Lipids and lipid management in diabetes
Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 117 · see citing works
Apolipoprotein C-III
Kohan, A. B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000136 · Cited by 113 · see citing works
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL)
Huang, J.-K., & Lee, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084300 · Cited by 111 · see citing works
Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100 · see citing works
Apolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98 · see citing works
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes
Hiukka, A., Fruchart‐Najib, J., Leinonen, E. S., Hilden, H., Fruchart, J., & Taskinen, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1753-z · Cited by 96 · see citing works
Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95 · see citing works
Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction
Kawakami, A., Osaka, M., Tani, M., Azuma, H., Sacks, F. M., Shimokado, K., & Yoshida, M. (2008) · Circulation · doi:10.1161/circulationaha.108.784785 · Cited by 92 · see citing works
Retracted
Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
Keirns, B. H., Sciarrillo, C. M., Koemel, N. A., & Emerson, S. R. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.73 · Cited by 86 · see citing works
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70 · see citing works
Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70 · see citing works
Effects of bariatric surgery on lipid-lipoprotein profile
Piché, M., Tardif, I., Auclair, A., & Poirier, P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154441 · Cited by 70 · see citing works
Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII
Li, H., Han, Y., Qi, R., Wang, Y., Zhang, X., Yu, M., Tang, Y., Wang, M., Shu, Y.-N., Huang, W. Y., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv192 · Cited by 64 · see citing works
Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000199815.46720.ca · Cited by 64 · see citing works
Untitled work
Ginsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64 · see citing works
Genetically modified pigs to model human diseases
Flisikowska, T., Kind, A., & Schnieke, A. (2013) · Journal of Applied Genetics · doi:10.1007/s13353-013-0182-9 · Cited by 63 · see citing works
New Therapies for Lowering Triglyceride-Rich Lipoproteins
Rosenson, R. S., Shaik, A., & Song, W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.051 · Cited by 67 · see citing works
Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease
Ooi, E. M. M., Chan, D. T., Watts, G. F., Chan, D. C., Ng, T. W., Dogra, G. K., Irish, A. B., & Barrett, P. H. R. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011163 · Cited by 63 · see citing works
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia
Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Rodriguez, C., Steiner, G. A., Mamer, O., & Davignon, J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.011 · Cited by 62 · see citing works
Self-citation
Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism
Chan, D. C., Nguyen, M. N., Watts, G. F., & Barrett, P. H. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2676 · Cited by 62 · see citing works
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia
Sundaram, M., Zhong, S., Khalil, M. B., Zhou, H., Jiang, Z. G., Zhao, Y., Iqbal, J., Hussain, M. M., Figeys, D., Wang, Y., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005108 · Cited by 58 · see citing works
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813942 · Cited by 58 · see citing works
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
Majali, K. A., Cooper, M. B., Staels, B., Luc, G., Taskinen, M., & Betteridge, D. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0092-4 · Cited by 58 · see citing works
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55 · see citing works
Intrahepatic Role of Exchangeable Apolipoproteins in Lipoprotein Assembly and Secretion
Sundaram, M., & Yao, Z. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241455 · Cited by 57 · see citing works
Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes
Koška, J., Yassine, H. N., Trenchevska, O., Sinari, S. A., Schwenke, D. C., Yen, F. T., Billheimer, D. D., Nelson, R. W., Nedelkov, D., & Reaven, P. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p064816 · Cited by 55 · see citing works
Management of Hypertriglyceridemia
Labossiere, R., & Goldberg, I. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_10 · Cited by 55 · see citing works
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 56 · see citing works
Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease
Hyysalo, J., Stojkovic, I., Kotronen, A., Hakkarainen, A., Sevastianova, K., Makkonen, J., Lundbom, N. M. I., Rissanen, A., Krauss, R. M., Melander, O., et al. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07045.x · Cited by 53 · see citing works
ApoCIII: A multifaceted protein in cardiometabolic disease
D’Erasmo, L., Costanzo, A. D., Gallo, A., Bruckert, É., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 52 · see citing works
Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism
Mauger, J., Couture, P., Bergeron, N., & Lamarche, B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500455-jlr200 · Cited by 51 · see citing works
Triglyceride-Rich Lipoprotein-Associated Apolipoprotein C-III Production Is Stimulated by Plasma Free Fatty Acids in Humans
Pavlic, M., Valéro, R., Duez, H., Xiao, C., Szeto, L., Patterson, B. W., & Lewis, G. F. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.169383 · Cited by 52 · see citing works
Self-citation
Proteomic analysis of human very low‐density lipoprotein by two‐dimensional gel electrophoresis and MALDI‐TOF/TOF
Mancone, C., Amicone, L., Fimia, G. M., Bravo, E., Piacentini, M., Tripodi, M., & Alonzi, T. (2006) · PROTEOMICS · doi:10.1002/pmic.200600339 · Cited by 51 · see citing works
Apolipoprotein CIII and Atherosclerosis
Bobik, A. (2008) · Circulation · doi:10.1161/circulationaha.108.794081 · Cited by 51 · see citing works
Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII
Wei, J., Ouyang, H., Wang, Y., Pang, D., Cong, N., Wang, T., Leng, B., Li, D., Li, X., Wu, R., et al. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08401.x · Cited by 50 · see citing works
Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., & Stalenhoef, A. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.002 · Cited by 50 · see citing works
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies
Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47 · see citing works
Large triglyceride-rich lipoproteins in hypertriglyceridemia are associated with the severity of acute pancreatitis in experimental mice
Zhang, Y., He, W., He, C., Wan, J., Lin, X., Zheng, X., Li, L., Li, X., Yang, X., Yu, B., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1969-3 · Cited by 47 · see citing works
ApoE ε2/ε3/ε4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome
Olivieri, O., Martinelli, N., Bassi, A., Trabetti, E., Girelli, D., Pizzolo, F., Friso, S., Pignatti, P. F., & Corrocher, R. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0142-y · Cited by 45 · see citing works
The physiology of MASLD: molecular pathways between liver and adipose tissues
Lee, W., Kipp, Z. A., Bates, E. A., Pauss, S. N., Martinez, G. J., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20257571 · Cited by 47 · see citing works
Effects of Bariatric Surgery on Hepatic and Intestinal Lipoprotein Particle Metabolism in Obese, Nondiabetic Humans
Padilla, N., Maraninchi, M., Béliard, S., Berthet, B., Nogueira, J. P., Wolff, E., Nicolay, A., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303849 · Cited by 43 · see citing works
Dose-Dependent Effect of Rosuvastatin on VLDL–Apolipoprotein C-III Kinetics in the Metabolic Syndrome
Ooi, E. M. M., Watts, G. F., Chan, D. C., Chen, M., Nestel, P. J., Sviridov, D., & Barrett, P. H. R. (2008) · Diabetes Care · doi:10.2337/dc08-0358 · Cited by 41 · see citing works
Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
Yan, H., Niimi, M., Matsuhisa, F., Zhou, H., Kitajima, S., Chen, Y., Wang, C., Yang, X., Yao, J. Q., Yang, D., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314368 · Cited by 39 · see citing works
Lipid accumulation product (LAP) as a potential index to predict risk of insulin resistance in young, non-obese Asian Indian males from Southern India: observations from hyperinsulinemic-euglycemic clamp studies
Shajith Anoop, S., Dasgupta, R., Rebekah, G. J., Jose, A., Inbakumari, M., Geethanjali, F. S., & Thomas, N. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002414 · Cited by 39 · see citing works
High-density lipoprotein and transport of cholesterol and triglyceride in blood
Brown, W. V. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.02.001 · Cited by 39 · see citing works
Relationship between serum adiponectin level and lipid composition in each lipoprotein fraction in adolescent children
Okada, T., Saito, E., Kuromori, Y., Miyashita, M., Iwata, F., Hara, M., & Harada, K. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.030 · Cited by 39 · see citing works
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38 · see citing works
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 39 · see citing works
APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J. F., Almeida, M., Sim, X., Lerner, M. R., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01531-8 · Cited by 39 · see citing works
Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies
Hayashi, T., Hirano, T., Yamamoto, T., Ito, Y., & Adachi, M. (2006) · Metabolism · doi:10.1016/j.metabol.2006.02.014 · Cited by 37 · see citing works
Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII
Ding, Y., Wang, Y., Zhu, H., Fan, J., Yu, L., Liu, C., & Liu, E. (2010) · Transgenic Research · doi:10.1007/s11248-010-9467-5 · Cited by 36 · see citing works
A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II
Meyers, N. L., Larsson, M., Olivecrona, G., & SMALL, D. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629865 · Cited by 34 · see citing works
Parallel increase of plasma apoproteins C‐II and C‐III in Type 2 diabetic patients
Béliard, S., Nogueira, J. P., Maraninchi, M., Lairon, D., Nicolay, A., Giral, P., Portugal, H., Vialettes, B., & Valéro, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02757.x · Cited by 34 · see citing works
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33 · see citing works
Fibrates and coronary risk reduction
Steiner, G. A. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.04.002 · Cited by 33 · see citing works
Self-citation
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Yang, D., Zhang, J., Xu, J., Zhu, T., Fan, Y., Fan, J., & Chen, Y. E. (2013) · Journal of Visualized Experiments · doi:10.3791/50957 · Cited by 32 · see citing works
Low High-Density Lipoprotein and Risk of Myocardial Infarction
Ramirez, A., & Hu, P. P. (2015) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s26624 · Cited by 31 · see citing works
Association Between Glycemic Control and Morning Blood Pressure Surge With Vascular Endothelial Dysfunction in Type 2 Diabetic Patients
Yoda, K., Inaba, M., Hamamoto, K., Yoda, M., Tsuda, A., Mori, K., Yamada, S., Emoto, M., Koyama, H., & Imanishi, Y. (2013) · Diabetes Care · doi:10.2337/dc13-1102 · Cited by 31 · see citing works
Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 30 · see citing works
Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph
Fei, W., Kohan, A. B., Dong, H. H., Yang, Q., Xu, M., Huesman, S., Lou, D., Hui, D. Y., & Tso, P. (2014) · Physiological Reports · doi:10.1002/phy2.247 · Cited by 29 · see citing works
Effects of atorvastatin and n−3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity
Chan, D. C., Nguyen, M. N., Watts, G. F., Ooi, E. M. M., & Barrett, P. H. R. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28422 · Cited by 29 · see citing works
Determinants of VLDL composition and apo B-containing particles in familial combined hyperlipidemia
Cruz‐Bautista, I., Mehta, R., Cabiedes, J., García-Ulloa, A. C., Guillén-Pineda, L. E., Almeda‐Valdés, P., Ramos, D. C., & Aguilar-Salinas, C. A. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.018 · Cited by 28 · see citing works
The Complex Metabolic Mechanisms Relating Obesity to Hypertriglyceridemia
Eckel, R. H. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.233049 · Cited by 28 · see citing works
Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature
Wölter, M., Röwer, C., Koy, C., Rath, W. H., Pecks, U., & Glocker, M. O. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.04.027 · Cited by 27 · see citing works
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 27 · see citing works
Apolipoprotein CIII Induces Monocyte Chemoattractant Protein-1 and Interleukin 6 Expression Via Toll-Like Receptor 2 Pathway in Mouse Adipocytes: Retracted
Abe, Y., Kawakami, A., Osaka, M., Uematsu, S., Akira, S., Shimokado, K., Sacks, F. M., & Yoshida, M. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.210427 · Cited by 26 · see citing works
Retracted
Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
Sahebkar, A., Simental‐Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., Ruscica, M., & Reiner, Ž. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.008 · Cited by 25 · see citing works
Insulin resistance and lipid disorders
Miccoli, R., Keyzer, D. D., Penno, D. G., & Prato, D. S. D. (2008) · Future Lipidology · doi:10.2217/17460875.3.6.651 · Cited by 24 · see citing works
A new multifunctional hydroxytyrosol-fenofibrate with antidiabetic, antihyperlipidemic, antioxidant and antiinflammatory action
Xie, Y., Xu, Y.-H., Chen, Z., Lu, W.-F., Li, N., Wang, Q., Shao, L., Li, Y., Yang, G., & Bian, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.073 · Cited by 23 · see citing works
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
Sokolov, V. V., Helmlinger, G., Nilsson, C. A. M., Zhudenkov, K., Skrtic, S., Hamrén, B., Peskov, K. V., Hurt‐Camejo, E., & Jansson‐Löfmark, R. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m092486 · Cited by 23 · see citing works

Lipoprotein (VLDL) Apolipoprotein C-III Is Strongly Related to the Concentration and Level of Production of VLDL Triglyceride in Male Subjects with Different Body Weights and Levels of Insulin Sensitivity
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2013)
Self-citation
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia
Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Rodriguez, C., Steiner, G. A., Mamer, O., & Davignon, J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.011 · Cited by 62 · see citing works
Self-citation
Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density
Lipoprotein Apolipoprotein, B., Apolipoprotein, L., Metabolism, A.-I., Chan, D. C., Nguyen, M. N., Watts, G. F., Hugh, P., & Barrett, R. (2013)
Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism
Chan, D. C., Nguyen, M. N., Watts, G. F., & Barrett, P. H. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2676 · Cited by 62 · see citing works
Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70 · see citing works

Authors: Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G.
Affiliations: Montreal Clinical Research Institute (CA)
Washington University in St. Louis (US)
Toronto General Hospital (CA)
Corresponding author: Cohn, Jeffrey S.
ORCID: Cohn, Jeffrey S.
Patterson, Bruce W.
Davignon, Jean
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2004-08
Volume: 89
Issue: 8
Pages: 3949-3955
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2003-032056
OpenAlex: W1994130325
Cited by: 170
References: 58
Citations by year: 2026: 4 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 12 · 2019: 10 · 2018: 5 · 2017: 7 · 2016: 9 · 2015: 10 · 2014: 8 · 2013: 15 · 2012: 9
FWCI: 5.01
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords: apolipoprotein C-III, VLDL triglycerides, hypertriglyceridemia, insulin sensitivity, overweight, body mass index, fractional catabolic rate
MeSH terms: Adult, Apolipoproteins C, Body Weight, Humans, Insulin, Insulin Resistance, Kinetics, Lipoproteins, VLDL, Male, Middle Aged, Osmolar Concentration, Triglycerides, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks